Functionally, it was shown in these studies that HAS2-mediated HA synthesis increases proliferation and migration of VSMC. Recently, it was discovered that HAS1 is involved in migratory responses of VSMC as well. 11 In addition, overexpression of HAS1 promotes adhesion of monocytes to the pericellular HA matrix suggesting that the HA matrix formed by HAS1 is involved in inflammatory responses. 12 Interestingly, in the study by Wilkinson et al 12 overexpression of all HAS isoforms led to decreased proliferation and migration rates, which is in contrast with the results of knocking down endogenous HAS1 and HAS2 that also inhibited proliferation and migration. 9, 10 Has2 knockout mice die at midgestation due to disturbed cardiac and vascular morphogenesis and defects in endothelial mesenchymal transition, suggesting that HAS2 fulfills critical physiological functions. 13 A fascinating example of physiological HA-driven neointimal hyperplasia is the closure of the ductus arteriosus Botalli. Here, prostaglandin E-mediated activation of the prostaglandin E receptor 4 promotes induction of Has2 and subsequently VSMC migration and the formation of an HA-rich intimal cushion. 14 However, the dilatory effect of prostaglandin E 2 keeps the ductus open. This remodeling process is essential in preparing the timely and rapid closure of the ductus arteriosus after cessation of prostaglandin E synthesis. In contrast to the lethal genetic deletion of Has2, deletion of Has1 or Has3 did not result in an obvious phenotype without pathophysiological challenge.
HAS2 probably represents an attractive target to inhibit neointimal hyperplasia because in vivo studies revealed that overexpression of Has2 in VSMC led to increased atherosclerosis in apolipoprotein E-deficient mice and to increased cuff-mediated neointimal hyperplasia in C57BL/6 mice. 15, 16 However, a limitation that needs to be considered is that those results reflect increased HA synthesis in medial VSMC because of Has2 overexpression in differentiated VSMC, and do not specifically reflect the physiological function of HAS2 during neointimal hyperplasia.
Because of the embryonic lethality of Has2-deficient mice and the importance of HAS2 for proper development of the cardiovascular system as well as for endothelial mesenchymal transition, it is doubtful that HAS2 represents a suitable therapeutic target. Therefore, the other HAS isoenzymes are of great interest with respect to their specific role in vascular pathologies. Whether HAS1 and HAS3 play a role in neointimal hyperplasia is not known. Similarly, other than the knowledge that HAS3 is upregulated in aged VSMC and that oxidized low-density lipoprotein and cholesterol induce HAS3 in human VSMC little is known about its regulation and function in VSMC. 17, 18 Hence, the aim of this study was to test the effect of loss of HAS3 during neointimal hyperplasia in vivo using mice with targeted deletion of Has3 and to study the underlying mechanisms in vitro.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Inhibition of Neointimal Hyperplasia in Has3-Deficient Mice
Has3-deficient mice displayed no differences with respect to body weight, blood glucose, and total cholesterol ( Figure I in the online-only Data Supplement). To address the role of HAS3 for VSMC phenotype in vivo, left carotid arteries of Has3-deficient mice and wild-type (WT) mice were ligated to induce neointimal hyperplasia driven by VSMC proliferation and migration. 19 In Has3-deficient mice, the neointimal area and neointimal/medial ratio were strongly reduced compared with WT mice ( Figure 1A and 1B) . In contrast, the medial and luminal areas were not changed ( Figure 1C) . A small reduction of the circumference of the external elastic lamina of ligated carotid arteries was observed ( Figure 1C ), indicating constrictive remodeling. Determination of cell density in the neointima suggested that both cell number and ECM declined proportionally in Has3-deficient mice after ligation ( Figure 1D ). Analysis of HA staining in control carotid arteries versus ligated WT carotids revealed an accumulation of HA both in the media and in the neointima after 28 days (Figure 2A ). Quantitative image analysis revealed less HA accumulation in the whole vessel (Figure 2A and 2B) in Has3-deficient mice after ligation. Interestingly, the difference was pronounced in the media ( Figure 2B ). In addition, after ligation expression of Has1 and Has2 were not further upregulated in Has3-deficient mice compared with WT, thereby excluding a compensatory counter regulation in response to Has3 deficiency ( Figure 2C and 2D) . Has3 mRNA was not detected in Has3-deficient mice (not shown).
To gain further mechanistic insight, ligated carotid arteries were investigated 5 days after ligation. As evidenced by 5-bromo-2′-deoxyuridine staining, the proliferation rate was not affected in the neointima of Has3-deficient compared with WT controls ( Figure 3A ). In addition, neither apoptotic rate ( Figure 3B ) nor immunostaining of α smooth muscle actin were affected ( Figure 3C ) 5 days after ligation. Furthermore, mRNA of Acta2 and SM22alpha were determined. Both markers of differentiated VSMC were strongly downregulated in response to ligation as expected. However, the extent of this downregulation was not different between genotypes ( Figure 3D ).
Next, it was addressed if Has3 deficiency might have general effects on endothelial function that might result in changes of ligand-induced vasodilatation and blood pressure. First, expression of endothelial nitric oxide synthase was found to be unaffected in aortas of WT versus Has3-deficient mice ( Figure 4A ). Likewise, acetylcholine-induced vasorelaxation was not affected ( Figure 4B ) as well as relaxation in response to an exogenous NO donor (S-nitroso-N-acetyl-d,lpenicillamine) and contraction in response to phenylephrine ( Figure 4C and 4D). Furthermore, arterial blood pressure of Has3-deficient mice was similar to WT mice ( Figure 4E ). To address the question whether the observed phenotype might involve changes in the oxidative stress response, oxyblot analysis was performed. No differences in oxidative protein modifications were observed between genotypes ( Figure 4F ).
All things considered, an effect of Has3-deletion on vascular tone and reagibility can be excluded as the mechanism underlying reduced neointimal hyperplasia in Has3-deficient mice.
Attenuated Transcriptional Response in Has3-
Deficient Mice After Carotid Artery Ligation
In search of the underlying mechanisms, genome-wide transcriptome analysis of control and ligated carotids was performed 5 days after ligation. In WT mice, 8006 transcripts were differentially regulated when comparing ligated carotid arteries to nonligated control carotids ( Figure II in the onlineonly Data Supplement). In contrast, using identical experimental settings in Has3-deficient mice only 3635 transcripts were affected by the ligation suggesting a strong influence of Has3 deficiency on transcriptional responses to vessel injury. The dampened response in Has3-deficient mice can also be seen in the hierarchical clustering and the volcano plots shown in Figure III in the online-only Data Supplement. Next, the transcriptome data were analyzed for Kyoto Encyclopedia of Genes and Genomes pathways that were only significantly regulated in response to ligation in carotid arteries from WT and not in carotids from Has3-deficient mice (Table I in the onlineonly Data Supplement). Of note, various pathways related to the migratory SMC phenotype, ECM signaling, and general signaling leading to phenotypic activation were identified, such as regulation of actin cytoskeleton (mmu04810), vascular smooth muscle contraction (mmu04270), calcium-signaling pathway (mmu04020), focal adhesion (mmu04510), ECM-receptor interaction (mmu04512), phosphatidylinositol signaling system (mmu04070), inositol phosphate metabolism (mmu00562), and mitogen-activated protein kinase-signaling pathway (mmu04010). Expression of genes representing the oxidative stress response did not seem to be differentially regulated between the genotypes confirming the results from the Oxyblot analysis as indicated above ( Figure 4F ).
HAS3-Mediated HA Synthesis Promotes Migration and Proliferation
Analysis of the neointima as presented in Figures 1-3 revealed decreased neointimal hyperplasia in Has3-deficient mice because of proportional decrease in cells and matrix. Because neither 5-bromo-2′-deoxyuridine incorporation nor apoptosis were changed in Has3-deficient mice, it is likely that primarily migratory responses are affected. In line with this assumption was the finding that Pdgf-b mRNA, known to promote VSMC migration, 20, 21 was upregulated in WT after carotid artery ligation but not in Has3-deficient mice as determined by gene array analysis (NCBI GEO accession number GSE70410). To complement the results obtained in Has3-deficient mice in vitro, lentiviral shRNA was used to specifically knockdown HAS3 (shHAS3, Figure 5A ) in human VSMC. Lentiviral shHAS3 efficiently reduced HAS3 mRNA expression and reduced HA secretion into the cell culture medium ( Figure 5A ). As observed in the gene array analysis, PDGF-B mRNA expression was significantly reduced in shHAS3 cells ( Figure 5A ). Importantly, migration was diminished in shHAS3 as determined in a microchemotaxis chamber ( Figure 5B ). Neither the mitogenic response to PDGF-BB . HAS3 supports the migratory and proliferative phenotype of human coronary vascular smooth muscle cell (VSMC). A, HAS3 mRNA was reduced using lentiviral shRNA compared with nontargeting shRNA (sh-cont) in VSMC, leading to a diminished hyaluronan (HA) secretion, and a downregulation of PDGF-B mRNA. B, shHAS3 inhibited migration as determined by a modified Boyden-chamber microchemotaxis assay on collagen type 1-coated membranes and proliferation as determined by cell count. *P<0.05 versus control. C, shHAS3 reduced mRNA expression of a variety of migration-associated genes in VSMCs stimulated with platelet-derived growth factor BB (PDGF-BB; 10 ng/mL) for 24 hours. *P<0.05 versus sh-cont (control); 1-way ANOVA with Dunnett multiple comparison test; n=3 to 6. Data are mean±SEM. February 2016 ( Figure 5B) nor the apoptotic rate (data not shown) was significantly altered in shHAS3. The gene array and the in vitro migration data strongly suggested a role of HAS3-mediated HA synthesis in migration. In line with this assumption, the expression of a panel of genes involved in the migratory response was downregulated after knockdown of HAS3 in VSMC as determined by quantitative polymerase chain reaction ( Figure 5C ). Accordingly, the migratory response of VSMC to PDGF-BB was strongly increased in HAS3 overexpressing (HAS3oe) Finally, it was considered whether the inflammatory response was affected in Has3-deficient mice. Importantly, neointimal hyperplasia in normocholesteremic mice is considered mainly a model of VSMC-driven neointimal hyperplasia. 22 In the gene array analysis, expression of genes representing the inflammatory response was upregulated in both genotypes and also inflammatory Kyoto Encyclopedia of Genes and Genomes pathways were regulated in both genotypes.
mRNA expression of Tnfa, Ccl2 (monocyte chemotactic protein 1), and Il1b as determined by quantitative polymerase chain reaction in ligated carotid arteries, showed a strong increase compared with unligated controls. However, no differences between genotypes were observed (data not shown). Likewise, circulating cytokines were mostly unaffected except increased interleukin (IL)-13 and granulocyte-macrophage colony-stimulating factor ( Figure 6 ). Importantly, IL-13-primed macrophages are characterized by a more anti-inflammatory M2 phenotype and suppress proinflammatory type 1 macrophages, 23 which in turn have been shown to substantially promote neointima formation via promotion of VSMC proliferation and migration. 24 In contrast, granulocyte-macrophage colony-stimulating factor is thought to promote inflammation so that both proinflammatory and primarily anti-inflammatory cytokines seem to be induced in Has3 deficiency and the net outcome remains unknown. Taken together, reduced inflammation is unlikely the mechanism underlying reduced neointimal hyperplasia in Has3-deficient mice.
Discussion
This study is the first to address the specific role of HAS3 during experimental neointimal hyperplasia in vivo and shows a substantial reduction of neointimal hyperplasia in Has3-deficient mice. In response to the arterial injury, strong accumulation of HA was observed within the neointimal layer, in line with earlier results. 3, 25 In healthy vessels, HA matrix is mainly limited to the adventitial layer and the endothelial glycocalyx. Because HAS2 is pivotal for development of the cardiovascular system as well as endothelial mesenchymal transition, it is likely not a suitable therapeutic target with favorable benefit/risk ratios. Therefore, therapeutic strategies specifically inhibiting HAS3-mediated HA expression might be considered in the prevention of restenosis after surgical intervention. On the basis of the unaltered cell density in the neointima in vivo, a proportional decrease of both cell number and ECM is suggested in Has3-deficient mice. Gene expression of Acta2 and SM22alpha was reduced 5 days after ligation, indicating dedifferentiation of VSMC. However, Has3 deficiency did not affect the expression of differentiation markers. In addition, immunostaining of α smooth muscle actin and determination of proliferation and apoptosis revealed no changes between the genotypes 5 days after ligation. In search of the underlying mechanisms, effects of Has3-deficiency on endothelial function, blood pressure, inflammation, and the oxidative stress response were excluded.
Importantly, HA accumulation in the ligated vessels was reduced in Has3-deficient mice. Analysis of medial and intimal HA accumulation revealed that reduction of HA occurred also in the media of ligated carotids from Has3-deficient mice. In this context, it is important to consider that migration of VSMC from the media into the intima is one of the first steps during neointimal hyperplasia. PDGF-BB has been shown to promote formation of pericellular HA matrix in VSMC that, in turn, strongly promotes migration.
2 Therefore, HAS3 may be involved in the induction of the provisional HA-rich ECM in the media and neointima of ligated carotid arteries and, in turn, promotes VSMC migration. In this context, it may be important that Pdgf-b mRNA expression as assessed by gene array analysis was significantly upregulated in ligated WT carotids but not in Has3-deficient carotids in response to ligation. Furthermore, PDGF-B was reduced in VSMC after lentiviral knockdown of HAS3. This may represent a feed forward mechanism that further inhibits migratory responses in the absence of HAS3. On the basis of these findings and the literature, it is likely that HAS3 expression in VSMC promotes neointimal hyperplasia as opposed to HAS3 expression by other cell types, such as endothelial cells. This is also supported by the differentially regulated Kyoto Encyclopedia of Genes and Genomes pathways that point toward VSMC but not endothelial cells, and the in vitro results. In future studies, VSMC-specific deletion of Has3 may be used to further confirm the role of VSMC.
To further understand the underlying cellular mechanisms, mRNA expression in the uninjured and ligated carotids was analyzed in an unbiased genome-wide approach using gene array technology. This analysis revealed that in WT mice about twice as many transcripts are regulated after ligation when compared with Has3-deficient mice (8006 versus 3635). Furthermore, a variety of Kyoto Encyclopedia of Genes and Genomes pathways were identified, which were only differentially regulated in WT mice in response to carotid ligation but not in Has3-deficient mice. Among these pathways those related to the migratory VSMC phenotype (contractility and actin cytoskeleton), ECM signaling (focal adhesion kinase and ECM-receptor interactions), and general signaling (mitogen-activated protein kinase and phosphatidylinositol signaling system) seemed particularly interesting because they could represent avenues of phenotypic activation of VSMC in WT that were dampened in Has3-deficient mice. In line with these effects on transcriptional programs in vivo, we detected corresponding functional differences in VSMC after knockdown of HAS3 in vitro. Lentiviral knockdown of HAS3 inhibited migration in VSMC and proliferation was not altered. Conversely, overexpression of HAS3 also revealed that HAS3-mediated HA synthesis augmented mainly migration and to a lesser extent proliferation in human VSMC.
The in vivo role of RHAMM and CD44 in neointimal hyperplasia has been demonstrated before. With respect to RHAMM, a role in both migration but also proliferation and cell division fidelity has recently been proposed in vivo. 4, 26 In Rhamm-deficient mice, constrictive artery wall remodeling was reduced after carotid artery ligation improving the lumen caliber, but surprisingly did not alter the neointimal area itself. 5 Similarly, a role of CD44 in promoting neointimal hyperplasia has been proposed. 27 Although, this has not directly been shown by the use of knockout mice. Strong evidence however suggests that CD44 orchestrates also inflammatory responses in vivo, for example, during atherosclerosis. 28, 29 Interestingly, it is known that inflammatory stimuli induce CD44 expression in VSMC. 30, 31 Toll-like receptors are also involved in neointimal hyperplasia. 32, 33 However, from the data presented here it cannot be concluded which of the receptors CD44 or RHAMM or even alternative HA receptors, such as toll-like receptor 2, toll-like receptor 4, LYVE1 (lymphatic vessel endothelial hyaluronan receptor), and HARE (hyaluronan receptor for endocytosis) are involved in the in vivo response and the inhibition of neointimal hyperplasia. For this purpose, future in vivo studies using the respective receptor knockouts or pathway inhibitors are needed.
Collectively, it is demonstrated here (1) that Has3 deletion inhibits neointimal hyperplasia and (2) that loss of HAS3-dependent synthesis of HA decreases PDGF-BB-mediated migration of VSMC. We conclude that HAS3 is a critical player in the phenotypic activation of medial VSMC during neointimal hyperplasia and may represent a suitable therapeutic target.
